Stockholm Ischemic Heart Disease Study

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
Stockholm Ischemic Heart Disease Study On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Stockholm Ischemic Heart Disease Study All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Stockholm Ischemic Heart Disease Study
CDC on Stockholm Ischemic Heart Disease Study
Stockholm Ischemic Heart Disease Study in the news
Blogs on Stockholm Ischemic Heart Disease Study
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for Stockholm Ischemic Heart Disease Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Stockholm Ischemic Heart Disease study is a randomized open label trial that assessed the effect of clofibrate and nicotinic acid vs placebo on ischemic heart disease mortality.

Study Description

Study Description
Study Design
Allocation	Randomized
Endpoint	Ischemic heart disease death
Masking	Open label
Study Details
Primary Purpose
Condition	Survivors of a myocardial infarction
Study Arms	Clofibrate and nicotinic acid Control
Population Size	555 subjects